Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

RLMD US Equity

Relmada Therapeutics, Inc.Health Care · Pharmaceutical Preparations · CIK 1553643 · FY ends Dec 31
$4.83
-0.02 (-0.41%)
USD · as of 2026-08-19 · marketstack

RLMD · 10-K · period ended 2022-12-31

← all RLMD documents
filed 2023-03-23 · EDGAR original ↗

Our rendering of the filing — original pagination and typography are not reproduced, and tables are reduced to their short label cells (the figures live on FA). Nothing is summarized: every line below is the filing's own text.

blocks 1,8932,492 of 2,904271k characters rendered

ITEM 7. MANAGEMENT’S DISCUSSION AND

ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The information and financial data discussed

below is derived from the consolidated financial statements of Relmada for the years ended December 31, 2022 and 2021. The consolidated

financial statements of Relmada were prepared and presented in accordance with generally accepted accounting principles in the United

States. The information and financial data discussed below is only a summary and should be read in conjunction with the historical financial

statements and related notes of Relmada contained elsewhere in this Report. The consolidated financial statements contained elsewhere

in this Report fully represent Relmada’s financial condition and operations; however, they are not indicative of the Company’s

future performance. See “Cautionary Note Regarding Forward Looking Statements” above for a discussion of forward-looking

statements and the significance of such statements in the context of this Annual Report.

This discussion contains forward-looking statements

reflecting our current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in

these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors”

and elsewhere herein. The information and financial data discussed below is only a summary and should be read in conjunction with the

historical financial statements and related notes of Relmada Therapeutics, Inc. contained elsewhere in this document. Relmada’s

current consolidated financial position and consolidated results of operations; are not necessarily indicative of the Company’s

future performance. See “Cautionary Note Regarding Forward Looking Statements” above for a discussion of forward-looking

statements and the significance of such statements in the context of this document.

Our Corporate History and Background

Relmada Therapeutics, Inc. is a clinical-stage,

publicly traded biotechnology company developing NCEs that potentially address areas of high unmet medical need in the treatment of depression

and other CNS diseases.

The Company’s lead product candidate, esmethadone,

is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.

On October 15, 2019, we reported top-line data

from study REL-1017-202. This was a double-blind, placebo-controlled Phase 2 clinical trial evaluating the safety, tolerability and efficacy

of two doses of REL-1017, 25 mg once a day and 50 mg once a day, as an adjunctive treatment in patients with MDD, who experienced an inadequate

response to 1 to 3 treatments with an antidepressant medication.

On December 20, 2020, the Company announced that

the first patient had been enrolled in the first Phase 3 clinical trial (RELIANCE I) of REL-1017, as an adjunctive treatment for MDD.

On April 1, 2021, Relmada announced the initiation

of RELIANCE II, the second of two sister pivotal Phase 3 clinical trials (RELIANCE I and RELIANCE II) of REL-1017, as an adjunctive treatment

for MDD. Patients who complete RELIANCE I and RELIANCE II are eligible to rollover into the long-term, open-label study, which also includes

subjects who had not previously participated in a REL-1017 clinical trial.

On October 4, 2021, Relmada announced the initiation

of the RELIANCE III study, the monotherapy trial for the Company’s lead product candidate, REL-1017.

On August 9, 2022, Relmada announced that the

FDA granted Fast Track designation to REL-1017 as a monotherapy for the treatment of MDD.

On October 13, 2022, Relmada announced that its

RELIANCE III study, evaluating REL-1017 in the monotherapy setting for MDD, did not achieve its primary endpoint, which was a statistically

significant improvement in depression symptoms compared to placebo as measured by MADRS on Day 28. In the study, the REL-1017 treatment

arm showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for the placebo arm, a higher than expected placebo response.

On December 7, 2022, Relmada announced that its RELIANCE I study, evaluating

REL-1017 as an adjunctive treatment for MDD, did not achieve its primary endpoint, which was a statistically significant improvement in

depression symptoms compared to placebo as measured by MADRS on Day 28. In the study, the REL-1017 treatment arm (n= 113) showed a MADRS

reduction of 15.1 points at Day 28 versus 12.9 points for the placebo arm (n=114), which is a clinically meaningful difference of 2.2

points on the MADRS, as well as a statistically significant difference in the response rate, with a response rate of 27.2% on placebo

vs 39.8% in the REL1017 arm (p<0.05).

34

In addition, in order to support potential regulatory

submissions seeking approval for REL-1017 as adjunctive and monotherapy treatment, the FDA confirmed that, based on what is known at

this time, Relmada will not be required to conduct a two-year carcinogenicity study of REL-1017, as sufficient clinical data have been

generated to date. The FDA also confirmed that Relmada does not need to conduct a TQT cardiac study in humans to support cardiac safety

in potential regulatory submissions for REL-1017, as the data already provided and the data to be generated by the Phase 3 program will

be adequate to evaluate the cardiac safety profile of REL-1017.

We have not generated revenues and do not anticipate

generating revenues for the foreseeable future. We had a net loss of approximately $157,043,800 and $125,751,800 for the years ended December

31, 2022 and 2021, respectively. At December 31, 2022, we have an accumulated deficit of approximately $462,110,900.

Results of Operations

For the Year Ended December 31, 2022 vs the Year Ended December

31, 2021

Research and Development Expense

Total research and development expense for the

year ended December 31, 2022 was approximately $113,323,000, as compared to $90,621,600 for the same period of 2021, an increase of $22,701,400.

The increase in research and development expense was primarily due to:

● Increase in pre-clinical and toxicology expenses of $225,500;

General and Administrative Expense

Total general and administrative expense for the

year ended December 31, 2022 was approximately $47,926,100, as compared to $35,081,900 for the same period of 2021, an increase of $12,844,200.

The increase in general and administrative expenses was primarily due to:

Other Income, Net

Gain on settlement fees was approximately $6,351,600 received from

a settlement during 2022.

Interest/investment income was approximately $2,659,400

for the year ended December 31, 2022 compared to approximately $1,199,100 for the same period of 2021, an increase of $1,460,300. The

increase was primarily related to a lower average investment balance during 2021 as compared to 2022.

Realized loss on short-term investments was approximately

$585,500 compared to approximately $636,000 for the same period of 2021, a decrease of $50,500. The decrease was related to the timing

of the sales of short-term investments along with market conditions.

Unrealized loss on short-term investments was

approximately $4,220,300 compared to approximately $611,400 for the same period of 2021, an increase of $3,608,900. The increase was related

to the market conditions.

Income Taxes

The Company did not provide for income taxes

for the years ended December 31, 2022 and 2021, since there was a loss and a full valuation allowance against all deferred tax assets.

Net Loss

The Company recorded a net loss of approximately

$157,043,800 and $125,751,800 or $5.30 and $7.16 per common share, basic and diluted, during the years ended December 31, 2022 and 2021,

respectively, based on the factors described above.

35

Liquidity

As shown in the accompanying financial statements,

the Company incurred negative operating cash flows of $103,801,617 for the year ended December 31, 2022 and has an accumulated deficit

of $462,110,935 from inception through December 31, 2022.

Relmada has funded its past operations through

equity raises and most recently in the year ended December 31, 2022, Relmada raised $42,728,599 in net proceeds from the sale of common

stock, $1,264,523 through the exercise of warrants, and $703,720 through the exercise of options.

Management believes that due to the recent equity

raises completed and exercises of options and warrants and the resulting cash position on its balance sheet, it has obtained sufficient

funding, based on its budgeted cash flow requirements, to continue ongoing operations for at least 12 months from the filing of this

annual report.

The following table sets forth selected cash flow information for

the periods indicated below:

For the Year Ended For the Year Ended

December 31, December 31,

For the year ended December 31, 2022, cash used in operating activities

was $103,801,617 primarily due to the net loss of $157,043,823. This was offset by non-cash expenses which primarily consisted of stock-based

compensation of $44,194,765 and a gain on settlement of $6,351,606. There were realized and unrealized losses on short term investments

of $585,522 and $4,220,255, respectively. In addition, there were increases in operating assets and liabilities for the year ended December

31, 2022 of $10,593,270.

For the year ended December 31, 2021, cash used

in operating activities was $91,873,395 primarily due to the net loss of $125,751,809. This was offset by non-cash expenses which primarily

consisted of stock-based compensation of $40,494,476 and depreciation expense of $1,258. There were realized and unrealized losses on

short term investments of $636,012 and $611,382, respectively. In addition, there were increases in operating assets and liabilities

for the year ended December 31, 2021 of $7,864,714.

For the year ended December 31, 2022, cash provided

by investing activities was $19,733,609, due to $47,293,763 of purchases of short term investments offset by $67,027,372 of sales of short

term investments.

For the year ended December 31, 2021, cash used

in investing activities was $54,118,036, due to $222,981,675 of purchases of short term investments offset by $168,863,639 of sales of

short term investments.

Net cash provided by financing activities for

the year ended December 31, 2022, was $45,020,474 due to proceeds from issuance of common stock of $42,728,599, proceeds from warrants

exercised for common stock of $1,264,523, proceeds from options exercised for common stock of $703,720, proceeds from 16b short swing

profit of $373,632 offset by the payment of fees for warrants issued for common stock of $50,000.

Net cash provided by financing activities for

the year ended December 31, 2021, was $187,939,473 due to proceeds from issuance of common stock of $184,642,981, proceeds from warrants

exercised for common stock of $2,628,061, proceeds from options exercised for common stock of $668,431.

Effects of Inflation

Our assets are primarily monetary, consisting

of cash and cash equivalents. Because of their liquidity, these assets are not directly affected by inflation. Because we intend to retain

and continue to use our equipment, we believe that the incremental inflation related to replacement costs of such items will not materially

affect our operations. However, the rate of inflation affects our expenses, such as those for employee compensation and contract services,

which could increase our level of expenses and the rate at which we use our resources.

Lease Obligations

The Company is obligated to pay approximately

$274,000 under 2 office operative leases over the next year.

36

Seasonality

We do not have a seasonal business cycle.

Critical Accounting Policies and Use of Estimates

The preparation of financial statements in conformity

with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that

affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial

statements and the reported amounts of revenues and expenses for the reporting period. Management bases its estimates on historical experience

and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making

judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. On a continual basis,

management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience,

and reasonable assumptions. After such reviews, and if deemed appropriate, managements estimates are adjusted accordingly. Actual results

could differ from those estimates and assumptions under different and/or future circumstances. Management considers an accounting estimate

to be critical if:

We evaluate our estimates and assumptions on

an ongoing basis and none of the Company’s estimates and assumptions used within the consolidated financial statements involve

a high level of estimation uncertainty. For additional discussion regarding the application of the significant accounting policies, see

Note 2 to the Company’s consolidated financial statements included in this report.

Recent Accounting Pronouncements

The Company lists material recent accounting

pronouncements in Note 2 of the consolidated financial statements.

37

ITEM 7A. QUANTITATIVE AND QUALITATIVE

DISCLOSURES ABOUT MARKET RISK

Interest rate risk

Our cash and cash equivalents include all highly

liquid investments with an original maturity of three months or less. Our cash equivalents are in a money market account. Because of

the short-term maturities of our cash and cash equivalents, we do not believe that an increase in market rates would have a significant

impact on the realized value of our investments. We place our cash and cash equivalents on deposit with financial institutions in the

United States. The Federal Deposit Insurance Corporation limits coverage for all depository accounts. Our cash and cash equivalents at

times may exceed covered limits.

Foreign currency exchange risk

We currently have limited, but may in the future

have increased, clinical and commercial manufacturing agreements which are denominated in Euros or other foreign currencies. As a result,

our financial results could be affected by factors such as a change in the foreign currency exchange rate between the U.S. dollar and

the Euro or other applicable currencies, or by weak economic conditions in Europe or elsewhere in the world. We are not currently engaged

in any foreign currency hedging activities.

Market indexed security risk

We have issued warrants to various holders underlying

shares of our common stock. These warrants are re-measured to their fair value at each reporting period with changes in their fair value

recorded as derivative gain (loss) in the accompanying consolidated statement of operations. We use the Black-Scholes model for valuation

of the warrants.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY

DATA

Our audited consolidated financial statements

as of December 31, 2022 and 2021 for the years then ended are included beginning on Page F-1 immediately following the signature page

to this report. See Item 15 for a list of the financial statements included herein.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH

ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation

of our management, including our Chief Executive Officer and Chief Financial Officer, we carried out an evaluation of the effectiveness

of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange

Act. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, at December 31, 2022, such

disclosure controls and procedures were effective.

Disclosure controls and procedures are controls

and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the

Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC. Disclosure controls and procedures

include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed

or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial

Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

This Annual Report on Form 10-K does not include

an attestation report from our registered public accounting firm regarding internal control over financial reporting. Our internal control

over financial reporting was not subject to such attestation as we are a non-accelerated filer.

Limitations on the Effectiveness of Controls

Our disclosure controls and procedures are designed

to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of inherent limitations

in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have

been detected. Our Chief Executive Officer and Chief Financial Officer have concluded, based on his evaluation as of the end of the period

covered by this Report that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives

of our disclosure control system were met.

Changes in Internal Control Over Financial

Reporting

There were no changes in the Company’s

internal controls over financial reporting that occurred during the fourth quarter of the fiscal year covered by this Annual Report on

Form 10-K that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial

reporting.

38

Management’s Report on Internal Control

Over Financial Reporting

As required by the SEC rules and regulations for the implementation

of Section 404 of the Sarbanes-Oxley Act, our management is responsible for establishing and maintaining adequate internal control

over financial reporting. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability

of financial reporting and the preparation of our consolidated financial statements for external reporting purposes in accordance with

United States Generally Accepted Accounting Principles (GAAP). Our internal control over financial reporting includes those policies and

procedures that:

Because of its inherent limitations, internal

control over financial reporting may not prevent or detect errors or misstatements in our consolidated financial statements. Also, projections

of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in

conditions, or that the degree or compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of

our internal control over financial reporting at December 31, 2022. In making these assessments, management used the criteria set forth

by the Committee of Sponsoring Organizations of the Treadway Commission COSO (2013 framework). Based on our assessments and those criteria,

management determined that we did maintain effective internal control over financial reporting at December 31, 2022.

ITEM

9B. OTHER INFORMATION

On March 17, 2023, our Board of Directors unanimously

approved, subject to stockholder approval, an amendment to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”),

increasing by 2,500,000 shares the number of shares of our common stock that will be available for issuance of awards under the 2021 Plan.

The 2021 Plan as adopted and approved by our shareholders originally authorized awards for up to 1,500,000 shares of our common stock.

On May 25, 2022, shareholders approved an amendment to the 2021 Plan to increase the shares of the Company’s common stock available

for issuance thereunder by 3,900,000 shares.

The purpose of the 2021 Plan is to (a) enable

the Company and its affiliates to attract and retain the types of employees, directors and consultants who will contribute to the Company’s

long range success; (b) provide incentives that align the interests of employees, consultants and directors with those of the stockholders

of the Company; and (c) promote the success of the Company’s business, thus enhancing the value of the Company for the benefit

of its stockholders.

Administration. The 2021 Plan will be

administered by a committee (the “Committee”), or in the Board’s sole discretion by the Board. In case no Committee

has been appointed, the Board may appoint one or more members of the Board appointed by the Board to administer the 2021 Plan in accordance

with the terms of the 2021 Plan. The Board has appointed the Compensation Committee of the Board to administer the 2021 Plan.

Shares Available for Awards. Subject to

adjustment in certain circumstances in accordance with the terms of the 2021 Plan, we will reserve for issuance under the 2021 Plan no

more than 7,900,000 shares of common stock (subject to adjustment in certain circumstances as provided in the Plan). Shares of Common

Stock available for distribution under the 2021 Plan may consist, in whole or in part, of authorized and unissued shares, treasury shares

or shares reacquired by the Company in any manner. Shares of Common Stock subject to an award that expires or is canceled, forfeited,

or terminated without issuance of the full number of shares of Common Stock to which the award related, as well as any shares of common

stock subject to an award that are (a) tendered in payment of an option, (b) delivered or withheld by the company to satisfy any tax withholding

obligation, or (c) covered by a stock-settled stock appreciation right or other awards that were not issued upon the settlement of the

award, shall be added back to the shares of common stock available for issuance of awards or delivery under the 2021 Plan.

Available Awards. Awards that may be granted

under the 2021 plan include: (a) incentive stock options, (b) non-qualified stock options, (c) stock appreciation rights, (d) restricted

awards, (e) performance share awards, (f) cash awards, and (g) other equity-based awards.

Recipients of Grants. Incentive stock

options may be granted only to employees. Awards other than incentive stock options may be granted to employees, consultants and directors

and those individuals whom the Committee or the Board determines are reasonably expected to become employees, consultants and directors

following the grant date. Our principal executive officer, principal financial officer and other named executive officers are eligible

to participate in and receive awards under the 2021 Plan.

Term.

The 2021 Plan has a term of ten years.

This summary of the 2021 Plan is qualified in

its entirety by the full text of the 2021 Plan, which is filed as Exhibit 10.33 to this Report and is incorporated by reference herein.

The proposed amendment to the 2021 Plan will be

submitted for the approval of our shareholders at our 2023 Annual Meeting of Stockholders. If the proposed amendment is not approved by

the shareholders, the 2021 Plan will remain effective with respect to the number of shares of common stock originally authorized. Options

for 930,336 shares of commons stock were issued subject to approval by the shareholders of this amendment. If the amendment is not approved,

such options will be void.

ITEM 9C. DISCLOSURE REGARDING FOREIGN

JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

39

PART III

The information required for the Items contained

in Part III is incorporated herein by reference from our definitive proxy statement for our 2023 Annual Meeting of Stockholders

(the “Proxy Statement”), which will be filed with the SEC no later than 120 days after December 31, 2022.

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS,

AND CORPORATE GOVERNANCE

ITEM 11. EXECUTIVE COMPENSATION

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

MANAGEMENT

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND

DIRECTOR INDEPENDENCE

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

40

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

Financial Statement Schedules

Our consolidated financial statements are listed

on the Index to Financial Statements on this annual report on Form 10-K beginning on page F-1.

All financial statement schedules are omitted

because they are not applicable or the required information is shown in the financial statements or notes thereto.

Our independent registered public accounting firm is Marcum LLP (PCAOB

ID #688) of Houston, Texas.

41

RELMADA THERAPEUTICS, INC.

(INDEX TO FINANCIAL STATEMENTS)

Page

Report of Independent Registered Public Accounting Firm F-2

Consolidated Balance Sheets as of December 31, 2022 and 2021 F-3

Notes to Consolidated Financial Statements F-8

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING

FIRM

To the Stockholders and Board of Directors of

Relmada Therapeutics, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated

balance sheets of Relmada Therapeutics, Inc. (the “Company”) as of December 31, 2022 and 2021, the related consolidated statements

of operations, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2022,

and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements

present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of

its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles

generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility

of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We

are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and

are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules

and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the

standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the

financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were

we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an

understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the

Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to

assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that

respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial

statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well

as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

Critical audit matters are matters arising from

the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and

that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,

subjective, or complex judgments. We determined that there are no critical audit matters.

/s/ Marcum llp

Marcum llp

We have served as the Company’s auditor since 2014.

Houston, Texas

March 23, 2023

F-2

Relmada Therapeutics, Inc.

Consolidated Balance Sheets

As of As of

December 31, December 31,

Assets

Current assets:

Lease payments receivable – short term - 86,377

Liabilities and Stockholders’ Equity

Current liabilities:

Commitments and Contingencies (Note 7)

Stockholders’ Equity:

The accompanying notes are an integral part of

these consolidated financial statements.

F-3

Relmada Therapeutics, Inc.

Consolidated Statements of Operations

For the Years Ended December 31, 2022 and 2021

Operating expenses:

Other income (expenses):

Gain on settlement of fees 6,351,606 -

Realized loss on short-term investments (585,522 ) (636,012 )

Net loss per common share – basic and diluted $ (5.30 ) $ (7.16 )

The accompanying notes are an integral part of

these consolidated financial statements.

F-4

Relmada Therapeutics, Inc.

Consolidated Statements of Changes in Stockholders’

Equity

For the Years Ended December 31, 2022 and 2021

Common Stock Additional Paid-in Accumulated

Shares Par Value Capital Deficit Total

The accompanying notes are an integral part of

these consolidated financial statements.

F-5

Relmada Therapeutics, Inc.

Consolidated Statements of Cash Flows

For the Years Ended December 31, 2022 and 2021

Cash flows from operating activities

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation expense - 1,258

Change in operating assets and liabilities:

Cash flows from investing activities

Cash flows from financing activities

Payment of fees for warrants issued for common stock (50,000 ) -

Proceeds from options exercised for common stock 703,720 668,431

Proceeds from short swing profit, net 373,632 -

F-6

Relmada Therapeutics, Inc.

Consolidated Statements of Cash Flows (continued)

For the Years Ended December 31, 2022 and 2021

Supplemental disclosure of cash flow information:

Non-cash operating transactions:

Forgiveness of accounts payable related to gain $ 3,212,583 $ -

Non-cash investing and financing transactions:

Share exchange for Pre-funded warrants $ 1,452 $ -

Net exercise of Pre-funded warrants $ (1,452 ) $ -

The accompanying notes are an integral part of

these consolidated financial statements.

F-7

Relmada Therapeutics, Inc.

Notes to Consolidated Financial Statements

NOTE 1 - BUSINESS

Relmada Therapeutics Inc. (Relmada or the Company)

(a Nevada corporation) is a clinical-stage, publicly traded biotechnology company focused on the development of esmethadone (d-methadone,

dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone is a New Chemical Entity (NCE) that potentially

addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders.

In addition to the normal risks associated with

a new business venture, there can be no assurance that the Company’s research and development will be successfully completed or

that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry

including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological

innovations, dependence on key personnel, protection of proprietary technology, and compliance with the Food and Drug Administration

(FDA) and other governmental regulations and approval requirements.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements

and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.

GAAP). The consolidated financial statements include the Company’s accounts and those of the Company’s wholly-owned subsidiary.

All significant intercompany accounts and transactions have been eliminated in consolidation.

Liquidity

As shown in the accompanying consolidated financial

statements, the Company incurred negative operating cash flows of $103,801,617 for the year ended December 31, 2022 and has an accumulated

deficit of $462,110,935 from inception through December 31, 2022.

Relmada has funded its past operations through

equity raises and most recently in the year ended December 31, 2022, Relmada raised $42,728,599 in proceeds from the sale of common stock

through an ATM offering, $1,264,523 through the exercise of warrants, and $703,720 through the exercise of options.

Management believes that the Company’s

existing cash and cash equivalents will enable them to fund operating expenses and capital expenditure requirements for at least 12 months

from the issuance of these consolidated financial statements. Beyond that point management will evaluate the size and scope of any subsequent

operations and clinical trials that will affect the timing of additional financings through public or private sales of equity or debt

securities or from bank or other loans or through strategic collaboration and/or licensing agreements. Any such expenditures related

to any subsequent clinical trials will not be incurred until such additional financing is raised. Further, additional financing related

to subsequent trials does not affect the Company’s conclusion that based on the cash on hand and the budgeted cash flow requirements,

the Company has sufficient funds to maintain operations for at least 12 months from the issuance of these consolidated financial statements.

F-8

Relmada Therapeutics, Inc.

Notes to Consolidated Financial Statements

Use of Estimates

The preparation of financial statements in conformity

with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure

of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the

reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses,

and recorded amounts related to income taxes.

Cash and Cash Equivalents

The Company considers cash deposits and all highly

liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash deposits are

held at two high-credit-quality financial institutions. The Company’s cash balance of $5,395,905 at December 31, 2022 at these

institutions exceed federally insured limits.

Short-term Investments

The Company’s investments consist entirely

of mutual funds. The securities are measured at fair value based on the net asset value (“NAV”). The Company has adopted

FASB ASU 2016-01, Financial Instruments, for the year ended December 31, 2021 which requires substantially all equity investments in

nonconsolidated entities to be measured at fair value with recurring changes recognized in earnings, except for those accounted for using

equity method accounting. Changes in fair value of the securities are recorded as part of other income on the consolidated statement

of operations. Short term investment activity is presented in the investing activities section on the consolidated statement of cash

flows.

Short-term investments at December 31, 2022

consisted of mutual funds with a fair value of $142,926,781.

Patents

Costs related to filing and pursuing patent applications

are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.

Leases

The Company recognizes their leases with a term

of greater than a year on the balance sheet by recording right-of-use assets and lease liabilities. Leases can be classified as either

operating leases or finance leases. Operating leases will result in straight-line lease expense, while finance leases will result in

front-loaded expense. The Company’s lease consists of an operating leases for office space. The Company does not recognize a lease

liability or right-of-use asset on the balance sheet for short-term leases. Instead, the Company recognizes short-term lease payments

as an expense on a straight-line basis over the lease term. A short-term lease is defined as a lease that, at the commencement date,

has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain

to exercise.

Gain on Settlement

The Company recognizes a gain when cash (or other

assets, such as claims to cash) has been received without the expectation of repayment. A gain is recorded when the assets are readily

convertible to know amounts of cash or claims to cash. Gains are reported as part of other income (expense) on the consolidated statement

of operations. The Company recorded an gain on settlement of $6,351,606 and $0 included in other income (expense) for the years ended

December 31, 2022 and 2021, respectively.

F-9

Relmada Therapeutics, Inc.

Notes to Consolidated Financial Statements

Fair Value of Financial Instruments

The Company’s financial instruments primarily

include cash, short term investments derivative liabilities and accounts payable. Due to the short-term nature of cash and accounts payable

the carrying amounts of these assets and liabilities approximate their fair value. Derivatives are recorded at fair value at each period

end.

Fair value is defined as the price that would

be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at

the reporting date. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices

in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as

follows:

Level 1 Inputs - Unadjusted quoted prices in

active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 Inputs - Inputs other than quoted prices

included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices

for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are

not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment

speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.

Level 3 Inputs - Prices or valuation techniques

that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

The Company’s short-term investment instruments of $142,926,781

at December 31, 2022 are classified using Level 1 inputs within the fair value hierarchy because they are valued using NAV. Unrealized

gains and losses are recorded in the consolidated statement of operations as unrealized gain on short-term investments. The Company recorded

an unrealized loss of $4,220,255 and $611,382, included in other income (expense) for the years ended December 31, 2022 and 2021, respectively.

Fair Value on a Recurring Basis

As required by Accounting Standard Codification

(ASC) Topic No. 820 - 10 Fair Value Measurement, financial assets and liabilities are classified based on the lowest level of

input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to

the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement

within the fair value hierarchy levels.

F-10

Relmada Therapeutics, Inc.

Notes to Consolidated Financial Statements

Income Taxes

The Company accounts for income taxes using the

asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable

to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred

tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary

differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is

recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the

deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred

tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. At December

31, 2022 and 2021, the Company had recorded a valuation allowance to the full extent of the Company’s net deferred tax assets since

the likelihood of realization of the benefit does not meet the more likely than not threshold.

The Company files a U.S. Federal income tax return

and various state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for unrecognized tax

benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative

expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at December 31, 2022 and 2021.

The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2018 forward.

Research and Development

Research and development costs primarily consist

of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The

Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical

study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received

and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.

Stock-Based Compensation

The Company measures the cost of employee services

received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over

the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date

fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics

of those instruments.

Net Loss per Common Share

Basic net loss per common share attributable

to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common

shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per common share attributable

to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common

share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised

of Class A convertible preferred stock, Series A preferred stock, options and warrants to purchase common stock. For all periods presented,

there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net

losses in each period.

F-11

Relmada Therapeutics, Inc.

Notes to Consolidated Financial Statements

The potentially dilutive securities that would

be anti-dilutive due to the Company’s net loss are not included in the calculation of diluted net loss per share attributable to

common stockholders. The anti-dilutive securities are as follows (in common stock equivalent shares):

Year ended December 31, Year ended December 31,

Subsequent Events

The Company’s management reviewed all material

events through the date the financial statements were issued for subsequent event disclosure consideration.

Recent Accounting Pronouncements

In November 2021, the FASB issued ASU 2021-10,

“Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance”. The amendments

in this ASU require annual disclosures to increase the transparency of government assistance received by a business entity including

information about the nature of the government transactions, related accounting policy, the line items on the balance sheet and income

statement that are affected, amounts applicable to each financial statement line item, and significant terms and conditions of the transactions,

including commitments and contingencies. The amendments in this ASU are effective for annual periods beginning after December 15, 2021.

Early adoption is permitted. The Company adopted this standard effective January 1, 2022 and the standard did not have a significant

impact on our consolidated financial statements.

In October 2021, the FASB issued ASU 2021-08,

“Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”.

The amendments in this ASU require that an entity (acquirer) recognize, and measure contract assets and contract liabilities acquired

in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, as if it

had originated the contracts as of the acquisition date. The amendments in this ASU are effective for annual and interim periods beginning

after December 15, 2022. Early adoption is permitted. The Company will evaluate the impact of ASU 2021-08 on any business combinations

entered into the future.

In May 2021, the FASB issued ASU No. 2021-04, Earnings

Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718),

and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2021-04 outlines how an entity should

account for modifications made to equity-classified written call options, including stock options and warrants to purchase the entity’s

own common stock. The guidance in the ASU requires an entity to treat a modification of an equity-classified written call options that

does not cause the option to become liability-classified as an exchange of the original option for a new option. This guidance applies

whether the modification is structured as an amendment to the terms and conditions of the equity-classified written call option or as

termination of the original option and issuance of a new option. The guidance is effective prospectively for fiscal years beginning after

December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, including in an interim period as

of the beginning of the fiscal year that includes that interim period. The Company adopted this standard effective January 1, 2022 and

the standard did not have a significant impact on our consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12,

“Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which is intended to simplify various aspects

related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies

and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within

those fiscal years, beginning after December 15, 2020. The Company adopted this standard effective January 1, 2021 and the standard did

not have a significant impact on our consolidated financial statements.

F-12

Source: SEC EDGAR (public domain) · 10-K for the period ended 2022-12-31, filed 2023-03-23 · accession 0001213900-23-022463

Filing HTML rendered to line-structured narrative text by the shipped reducer (datafeeds.edgar_fulltext.visible_text, keep_table_headers=True): scripts and inline-XBRL headers are dropped, and table content is reduced to its short label cells — numeric table data is not rendered and is therefore not counted. The same rendering is used for every year, so a year-over-year comparison is like for like.

The text is our rendering of the filing, not a facsimile: original pagination, typography and tables are not reproduced, and the numbers live in the financial statements (FA).

The outline locates item HEADINGS in this document. Only Items 1A and 7 have certified boundaries elsewhere in the terminal (the redline and the narrative-overlap number); every span here runs from one heading found to the next heading found.

How the outline was chosen. It is the longest chain of item headings that runs forward through both the document and the standard item order: 20 headings are on that chain and 0 further heading-shaped lines are not — the table-of-contents echo of every item, cross-references and exhibit-list mentions. Each entry's length is measured from its heading to the next heading on the chain.